<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dutasteride: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dutasteride: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Dutasteride: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12405" href="/d/html/12405.html" rel="external">see "Dutasteride: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F163870"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Avodart</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866695"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACT Dutasteride;</li>
<li>APO-Dutasteride;</li>
<li>AURO-Dutasteride;</li>
<li>Avodart;</li>
<li>JAMP Dutasteride;</li>
<li>MED-Dutasteride;</li>
<li>MINT-Dutasteride;</li>
<li>PMS-Dutasteride [DSC];</li>
<li>PRIVA-Dutasteride;</li>
<li>RIVA-Dutasteride;</li>
<li>SANDOZ Dutasteride;</li>
<li>TEVA-Dutasteride</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F163887"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        5 Alpha-Reductase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F163872"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="64ef9771-0186-450c-8cac-9fbc347a4341">Benign prostatic hyperplasia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Benign prostatic hyperplasia (alternative agent):</b>
<b>Note:</b> Reserve use for patients with significantly enlarged prostates (prostate volume &gt;30 mL, prostate-specific antigen &gt;1.5 ng/mL, or palpable prostate enlargement on digital rectal exam) or those with hematuria associated with benign prostatic hyperplasia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34384237','lexi-content-ref-34384236','lexi-content-ref-McVary.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34384237','lexi-content-ref-34384236','lexi-content-ref-McVary.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 0.5 mg once daily alone or in combination with an alpha-1 adrenergic antagonist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34384237','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34384237','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990806"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment is necessary.</p></div>
<div class="block doha drugH1Div" id="F50988006"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied). Dutasteride is extensively hepatically metabolized and exposure could be increased in hepatic impairment, however, higher doses studied did not generally produce additional adverse effects.</p></div>
<div class="block doe drugH1Div" id="F163873"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F163837"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">Frequency of most adverse events (except prostate cancer high grade) tends to decrease with continued use (&gt;6 months). Frequency not always defined.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido (≤3%; incidence highest during first 6 months of therapy), gynecomastia (including breast tenderness, breast enlargement; ≤1%), increased luteinizing hormone, increased testosterone level, increased thyroid stimulating hormone level</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Impotence (≤5%; incidence highest during first 6 months of therapy), ejaculatory disorder (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Prostate cancer high grade (≤1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Angioedema, cardiac failure, depressed mood, dermatological reaction (serious), dizziness, hypersensitivity, localized edema, malignant neoplasm of breast (males), pruritus, skin rash, testicular pain, testicular swelling, urticaria</p></div>
<div class="block coi drugH1Div" id="F163851"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Clinically significant hypersensitivity to dutasteride, other 5-alpha-reductase inhibitors (eg, finasteride), or any component of the formulation; pregnancy.</p></div>
<div class="block war drugH1Div" id="F163835"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Diminished urinary flow: Carefully monitor patients with a large residual urinary volume or severely diminished urinary flow for obstructive uropathy; these patients may not be candidates for dutasteride therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prostate cancer: When compared to placebo, 5-alpha-reductase inhibitors (5-ARIs) have been shown to reduce the overall incidence of prostate cancer, although an increase in the incidence of high-grade prostate cancers has been observed; 5-ARIs are not approved in the United States or Canada for the prevention of prostate cancer.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CYP3A4 inhibitors: Use with caution with concurrent use of potent, chronic CYP3A4 inhibitors.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Other urological diseases, including prostate cancer, should be ruled out before initiating therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Blood donation: Avoid donating blood during or for 6 months following treatment cessation due to risk of administration to a transfusion recipient who is pregnant.</p>
<p style="text-indent:-2em;margin-left:4em;">• PSA monitoring: Reduces prostate specific antigen (PSA) by ~50% within 3 to 6 months of use. If following serial PSAs, re-establish a new baseline ≥3 months after treatment initiation; monitor PSA periodically thereafter. If interpreting an isolated PSA value in a patient treated for ≥3 months, then double the PSA value for comparison. PSA increases while on dutasteride should be considered suspicious; obtain serial PSA measurements and evaluate (Andriole 2006). Patients on a 5-ARI with any increase in PSA levels, even if within normal limits, should be evaluated; may indicate presence of prostate cancer.</p></div>
<div class="block foc drugH1Div" id="F163846"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Avodart: 0.5 mg [contains gelatin (bovine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg</p></div>
<div class="block geq drugH1Div" id="F163832"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F163852"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Avodart Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $37.90</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Dutasteride Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $0.16 - $6.05</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866696"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Avodart: 0.5 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg</p></div>
<div class="block adm drugH1Div" id="F163848"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> May be administered without regard to meals. Capsule should be swallowed whole; do not chew or open; contact with opened capsule can cause oropharyngeal irritation. Should not be touched or handled by patients who are or who may be pregnant.</p></div>
<div class="block hazard drugH1Div" id="F49104470"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 3]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>
<div class="block use drugH1Div" id="F163847"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Benign prostatic hyperplasia:</b> Treatment of symptomatic benign prostatic hyperplasia (BPH) as monotherapy (to improve symptoms, reduce the risk of acute urinary retention, and to reduce the risk of need for BPH-related surgery) or combination therapy with an alpha-1 adrenergic antagonist to reduce the risk of symptomatic progression (AUA [Lerner 2021a]; manufacturer's labeling).</p></div>
<div class="block off-label drugH1Div" id="F25725305"><span class="drugH1">Use: Off-Label: Adult</span><p>Male pattern baldness</p></div>
<div class="block mst drugH1Div" id="F56411511"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F163881"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F163839"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Dutasteride.<i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F163865"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Maximum serum concentrations reduced by 10% to 15% when taken with food; not clinically significant. Management: Administer without regard to meals. </p></div>
<div class="block rep_considerations drugH1Div" id="F54333470"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Dutasteride can be detected in semen; sperm count, semen volume, and sperm movement may be decreased, but the effect on male fertility is unknown.</p></div>
<div class="block pri drugH1Div" id="F163853"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and data from animal reproduction studies, in utero exposure to dutasteride may cause fetal harm. Use is contraindicated during pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">Capsules should not be handled by patients who are or who may be pregnant; if contact with a leaking capsule occurs, wash area immediately with soap and water.</p></div>
<div class="block brc drugH1Div" id="F20306062"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if dutasteride is present in breast milk.</p></div>
<div class="block mop drugH1Div" id="F163844"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">To interpret serial prostate-specific antigens (PSAs), establish a new PSA baseline ≥6 months after treatment initiation and monitor PSA periodically thereafter. International Prostate Symptom Score (baseline and 3 to 12 months after treatment initiation); urinalysis (baseline); objective and subjective signs of relief of benign prostatic hyperplasia and lower urinary tract symptoms (AUA [Lerner 2021a]; McVary 2022; manufacturer's labeling).</p></div>
<div class="block pha drugH1Div" id="F163834"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Dutasteride is a 4-azo analog of testosterone and is a competitive, selective inhibitor of both reproductive tissues (type 2) and skin and hepatic (type 1) 5α-reductase. This results in inhibition of the conversion of testosterone to dihydrotestosterone and markedly suppresses serum dihydrotestosterone levels.</p></div>
<div class="block phk drugH1Div" id="F163850"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Absorbed via skin when handling capsules </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: 300 to 500 L, ~12% of serum concentrations partitioned into semen </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 99% to albumin; ~97% to alpha<sub>1</sub>-acid glycoprotein; &gt;96% to semen protein </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism:   Hepatic via CYP3A4 and CYP3A5 isoenzymes (extensive); forms metabolites: 6-hydroxydutasteride has activity similar to parent compound, 4′-hydroxydutasteride and 1,2-dihydrodutasteride are much less potent than parent in vitro</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: ~60% (range: 40% to 94%) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Terminal: ~5 weeks </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak: 2-3 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces (40% as metabolites, ~5% as unchanged drug); urine (&lt;1% as unchanged drug); ~55% of dose unaccounted for</p></div>
<div class="block phksp drugH1Div" id="F51154003"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Dutasteride half-life increases with age.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F163855"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Exdart | Nuvodart</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Doxaten | Dutapil | Urocont</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Dutaglandin | Dutasterid accord | Dutasterid genericon</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo-dutasteride | Avodart</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Dutamax</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Dutasteride ab | Dutasteride krka | Dutasteride sandoz | Prostatex</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Dutalan | Dutasteride ecopharm</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Dastene | Dutasterida</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Dutasterid Spirig HC | Dutasterid xiromed</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Avodart</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Avolve | Dutasvitae</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Avodart</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Dutapros | Dutasterida | Dutasvitae | Dutaz | Urtal</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Adadut | Avodart | Dutalan | Dutamon | Dutasterid aristo | Reneten</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Dutascar | Dutasterid aristo | Dutasteride AXiromed</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Avoride | Dutasvitae | Truvera</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Avodart</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Dutasteride elvim | Dutasteride teva | Dutrys</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Bengiride | Dutaprost | Sigdutaster</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Avidart | Duagen | Dutacap | Dutaqur | Dutasterida apotex | Dutasterida aristo | Dutasterida aurovitas | Dutasterida cinfa | Dutasterida combix | Dutasterida kern pharma | Dutasterida krka | Dutasterida Mylan | Dutasterida pensa | Dutasterida qualigen | Dutasterida ratiopharm | Dutasterida sandoz | Dutasterida stada | Dutasterida tecnigen | Dutasterida teva | Dutasterida vir</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Dutasteride accord | Dutasteride krka | Dutasteride medical valley | Dutasteride mylan | Dutasteride ratiopharm | Dutasteride stada | Dutester</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Dutasteride accord | Dutasteride arrow | Dutasteride biogaran | Dutasteride cristers | Dutasteride eg | Dutasteride evolugen | Dutasteride krka | Dutasteride Mylan generiques | Dutasteride sandoz | Dutasteride teva | Dutasteride zentiva lab</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Zepron</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Dastidem | Duagen | Duaride | Dustezor | Rafuster</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo-dutasteride | Avodart</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Duprost | Duster | Dutacip | Dutrys</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Avodart</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Reinpid | Terod</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Dutasteride krka | Dutasteride rowa | Dutasteride teva | Quedute</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Armonia | Avodart</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Duprost | Durize | Dutagen | Dutas</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Decuster | Duagen | Durital | Dutas | Dutasteride accord | Dutasteride aristo | Dutasteride aurobindo | Dutasteride doc Generici | Dutasteride eg | Dutasteride germed | Dutasteride krka | Dutasteride Mylan Pharma | Dutasteride pensa | Dutasteride sandoz | Dutasteride tecnigen | Dutasteride teva | Dutasteride zentiva | Epiprostis | Prodirexan | Produtal | Produxen | Tasdurit</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Dutamax</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Avolve | Dutasteride av | Dutasteride za | Dutavolve | Zagallo</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Dutaliv | Dutamark | Dutasvitae | Tride</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Abboted | Adamo | Aduta | Ahngook dutasteride | Anadin | Anadine | Avodart | Avoduta | Avofina | Avostar | Avosteed | Avotan | Avotas | Avoterid | Avotwowin | Boryung dutasteride | CMduta | Daewoongbio dutasteride | Damodat | Daterin | Duabo | Duavo | Durocan | Dusta | Dutady | Dutaget | Dutalex sc | Dutalid | Dutarac | Dutard | Dutaride | Dutaron | Dutaska | Dutast | Dutatect sc | Dutavan | Dutazen | Duted | Duteron | Dutesmol | Humerina | I duta | Moplus | Neodart | One two steride | Prodart | Samchundang dutasteride | Taterin | Urodart | Yuhylyx | Zygard</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Avodart</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Dutasteride arrow | Dutasteride biogaran</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Dortilla | Dutasteride elvim | Dutasteride inteli</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Avodart</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Avidart | Avodart | Dutasteride elvim | Dutasteride teva | Dutrys</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Dusta</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Doferel</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Dutabit | Uroka</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Dutasteride accord | Dutasteride aurobindo | Dutasteride cf | Dutasteride sandoz | Dutasteride teva | Dutasteride xiromed</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Dutasteride medical valley</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Terod</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Dustatrig | Dustratrig | Dutaride | Dutasvitae | Lenomide | Prostasil</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Dutride</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">D dart</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Adadut | Avodart | Davoster | Dutafin | Dutasteride zentiva | Findarts | Geroladut</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Avodart</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Duagen | Dutasterida | Dutasterida aristo | Dutasterida aurovitas | Dutasterida bluepharma | Dutasterida Ciclum | Dutasterida krka | Dutasterida Pharmakern | Dutasterida sandoz | Dutasterida tecnigen | Dutasterida teva | Dutasterida toLife | Dutasterida zentiva</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Urocont</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Dutasvitae</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Asium | Avaterid | Avodart | Deridust | Dutalan | Dutasterida aurobindo | Dutasterida zentiva | Maxtrid</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Dutasterid | Dutasteride bakter | Gardium</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Duserex</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Dutasteride medical valley</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Avodart</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Amdut | Avodart | Dortilla | Dutasterid stada | Dutasteride teva</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Adadut | Avodart | Dutalan | Dutamed | Dutamon | Dutasterid cipla | Dutrys</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Duagen | Uroka</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Avodart</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Dutapros</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Budida | Dutasvitae | Nuvaniv | Rasteride</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Dustarin | Dutasteride vista | Prostid</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Avodart</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Avodart | Duract</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Amprovil</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Dagocti | Dutaon</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Avodart</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20357281">
<a name="20357281"></a>Andriole G, Bostwick DG, Brawley OW, et al, “Effect of Dutasteride on the Risk of Prostate Cancer,” <i>N Engl J Med</i>, 2010, 362(13):1192-202.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dutasteride-drug-information/abstract-text/20357281/pubmed" id="20357281" target="_blank">20357281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16600723">
<a name="16600723"></a>Andriole GL, Marberger M, and Roehrborn CG. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride. <i>J Urol</i>. 2006;175(5):1657-1662.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dutasteride-drug-information/abstract-text/16600723/pubmed" id="16600723" target="_blank">16600723</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Avodart (dutasteride) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; January 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20605255">
<a name="20605255"></a>Eun HC, Kwon OS, Yeon JH, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. <i>J Am Acad Dermatol</i>. 2010;63(2):252-258.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dutasteride-drug-information/abstract-text/20605255/pubmed" id="20605255" target="_blank">20605255</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34384237">
<a name="34384237"></a>Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I, initial work-up and medical management. <i>J Urol.</i> 2021a;206(4):806-817. doi:10.1097/JU.0000000000002183<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dutasteride-drug-information/abstract-text/34384237/pubmed" id="34384237" target="_blank">34384237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34384236">
<a name="34384236"></a>Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part II-surgical evaluation and treatment. <i>J Urol</i>. 2021b;206(4):818-826. doi:10.1097/JU.0000000000002184<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dutasteride-drug-information/abstract-text/34384236/pubmed" id="34384236" target="_blank">34384236</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-McVary.1">
<a name="McVary.1"></a>McVary KT. Medical treatment of benign prostatic hyperplasia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 23, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17110217">
<a name="17110217"></a>Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML, Wilson T, Rittmaster RS; Dutasteride Alopecia Research Team. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. <i>J Am Acad Dermatol</i>. 2006;55(6):1014-1023.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dutasteride-drug-information/abstract-text/17110217/pubmed" id="17110217" target="_blank">17110217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li></ol></div><div id="topicVersionRevision">Topic 8672 Version 252.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
